Table 1.
General characteristics of COVID-19 (n = 171) patients with neurological manifestation.
| Characteristics | N (%) |
|---|---|
| Mean Age, SD, IQR | 53.2, 15.5, 40–64 |
| Gender * | 159 |
| Male, n (%) | 106 (66.7) |
| Female, n (%) | 53 (33.7) |
| Neurological manifestation | 171 |
| Ischemic stroke, n (%) | 62 (36.2) |
| Hemorrhagic stroke, n (%) | 41 (24) |
| Encephalitis, n (%) | 24 (14) |
| CNS inflammatory, n (%) | 44 (25.7) |
| Encephalopathy, n (%) | 11 (6.4) |
| GBS and its variant, n (%) | 3 (2) |
| Olfactory bulb enhancement, n (%) | 3 (2) |
| Other cranial nerve enhancement, n (%) | 6 (3.5) |
| Others **, n (%) | 6 (3.5) |
| Severity of COVID-19 *** | 171 |
| Severe | 96 (56.2) |
| Non-Severe | 75 (43.8) |
| Outcomes | 171 |
| Fatal | 49 (28.7) |
| Non-fatal | 122 (71.3) |
Abbreviations: SD, Standard Deviation; IQR, Interquartile Range. * Gender data on 12 cases not available. ** Other includes pachymeningeal enhancement and nonspecific findings such as FLAIR hyperintensities in deep white matter. *** Severity based on Infectious Disease Society of America/American Thoracic Society. IDSA/ATS criteria.